Physician profile
Armando Dorta
NPI 1316676562
$4,049.86
in general payments reported to CMS, 2019-2025
14 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,729 · 2023: $866 · 2024: $140 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,311.50 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,885.82 | 2022-2025 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan, Linq II |
| Boston Scientific Corporation | $310.14 | 2022-2023 | Watchman Access System, Watchman |
| Biosense Webster, INC. | $231.99 | 2022-2023 | Carto 3 |
| Novo Nordisk INC | $144.65 | 2025 | Wegovy |
| Atricure, INC. | $140.17 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.29 | 2022 | |
| Cardiva Medical, INC. | $84.43 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Janssen Pharmaceuticals, INC | $37.32 | 2022-2023 | Xarelto |
| Ardelyx, INC. | $27.50 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.97 | 2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $23.58 | 2023 | Eliquis |
| Madrigal Pharmaceuticals | $15.67 | 2025 | Rezdiffra |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Lilly USA, LLC | $14.33 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armando Dorta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.